Literature DB >> 11843638

Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients.

Remco van Doorn1, Erik Scheffer, Rein Willemze.   

Abstract

OBJECTIVE: To determine the clinicopathologic features and the disease course of patients with follicular mycosis fungoides (MF).
DESIGN: A multicenter, 14-year, retrospective cohort analysis.
SETTING: Dutch Cutaneous Lymphoma Group. PATIENTS: Fifty-one patients with the clinicopathologic features of follicular MF with (n = 49) or without (n = 2) associated follicular mucinosis. Follow-up data were compared with those of 158 patients with the classic epidermotropic type of MF, including 122 patients with generalized plaque-stage MF (T2 N0 M0) and 36 patients with tumor-stage MF (T3 N0 M0). OBSERVATIONS: Characteristic clinical features not or rarely observed in classic MF were the preferential localization of the skin lesions in the head and neck region (45 of 51 patients), the presence of follicular papules, alopecia, acneiform lesions, mucinorrhoea, and often severe pruritus. Characteristic histologic findings were the presence of perifollicular neoplastic infiltrates with a variable degree of folliculotropism, but generally no epidermotropism, follicular mucinosis (49 of 51 cases), and often a considerable admixture of eosinophils and plasma cells. Response on initial treatment, risk of disease progression (development of extracutaneous disease and/or death from lymphoma), and disease-specific and overall survival of patients with follicular MF were worse than in classic MF patients. The actuarial disease-specific survival was 68% at 5 years and 26% at 10 years.
CONCLUSIONS: Follicular MF shows distinctive clinicopathologic features, is more refractory to treatment, and has a worse prognosis than the classic type of MF; it should be considered a distinct type of cutaneous T-cell lymphoma. Based on these results and those of other studies, we suggest the term follicular MF for cases with or without associated follicular mucinosis.

Entities:  

Mesh:

Year:  2002        PMID: 11843638     DOI: 10.1001/archderm.138.2.191

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  23 in total

Review 1.  Follicular mucinosis in patients with hematologic malignancies other than mycosis fungoides: A clinicopathologic study.

Authors:  Shamir Geller; Christian J Gomez; Patricia L Myskowski; Melissa Pulitzer
Journal:  J Am Acad Dermatol       Date:  2019-02-01       Impact factor: 11.527

2.  Incidental folliculotropic mycosis fungoides in a blepharoplasty specimen performed for dermatochalasis.

Authors:  H S Mudhar; N Tiffin; Z Currie; S Salvi
Journal:  Eye (Lond)       Date:  2014-01-10       Impact factor: 3.775

3.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.

Authors:  Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

Review 4.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

5.  Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides.

Authors:  Kelly M MacArthur; Neha Jariwala; Ellen J Kim; Alain H Rook
Journal:  Acta Derm Venereol       Date:  2017-03-10       Impact factor: 4.437

6.  [Folliculotropic mycosis fungoides].

Authors:  J Baratli; G Balakirski; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 7.  Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.

Authors:  Sara Berg; Jennifer Villasenor-Park; Paul Haun; Ellen J Kim
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

8.  Follicular mycosis fungoides - A report of four Indian cases.

Authors:  T Rajalakshmi; Y K Inchara; Meryl Antony
Journal:  Indian J Med Paediatr Oncol       Date:  2009-07

Review 9.  Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach.

Authors:  Ghadah I Al Hothali
Journal:  Int J Health Sci (Qassim)       Date:  2013-06

10.  Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Authors:  P Quaglino; H M Prince; R Cowan; M Vermeer; E Papadavid; M Bagot; O Servitjie; E Berti; E Guenova; R Stadler; C Querfeld; A M Busschots; E Hodak; A Patsatsi; J Sanches; M Maule; J Yoo; M Kevin; P Fava; S Ribero; L Zocchi; M Rubatto; M T Fierro; U Wehkamp; M Marshalko; C Mitteldorf; O Akilov; P Ortiz-Romero; T Estrach; L Vakeva; P A Enz; M Wobser; M Bayne; C Jonak; M Rubeta; A Forbes; A Bates; M Battistella; R Amel-Kashipaz; B Vydianath; A Combalia; E Georgiou; E Hauben; E K Hong; M Jost; R Knobler; I Amitay-Laish; D Miyashiro; J Cury-Martins; X Martinez; C Muniesa; H Prag-Naveh; A Stratigos; V Nikolaou; K Quint; C Ram-Wolff; K Rieger; R Stranzenbach; Á Szepesi; S Alberti-Violetti; E Felicity; L Cerroni; W Kempf; S Whittaker; R Willemze; Y Kim; J J Scarisbrick
Journal:  Br J Dermatol       Date:  2021-02-18       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.